SAN DIEGO, CA--(Marketwired - Apr 11, 2013) - NuVasive, Inc. (
With over 3,000 neurosurgeons and healthcare professionals expected to attend, this year's theme is "changing our culture to advance patient safety." NuVasive will demonstrate a comprehensive spine portfolio featuring several of our newest game changers, including the VuePoint ® II OCT System and the PCM ® Cervical Disc.
"As a global medical device company, we look forward to partnering with AANS to further superior outcomes and patient safety with our newest game changing products," said Alex Lukianov, Chairman and CEO of NuVasive. "As an XLIF ® patient myself, I know firsthand the safety concerns of most patients about to be treated with invasive surgery. Since NuVasive has redefined spine surgery with a revolutionary minimally disruptive approach, patients no longer have to undergo invasive spine procedures. Patients are often able to walk the same day of surgery, experience less blood loss, and spend less time in the hospital which helps patient's recover quickly and safely. We are very excited to participate at AANS to showcase XLIF and our entire portfolio of solutions for the spine."
AANS will host several leaders who pioneered the patient safety movement, including Donald Berwick, MD, former administrator of the Center of Medicare and Medicaid Services and Carolyn Clancy, MD, Director of the Agency for Healthcare Research and Quality (AHRQ).
NuVasive is scheduled to participate in the following events at AANS:
- NuVasive ® Exhibit Booth #1845: The NuVasive exhibit booth will feature a number of innovative, minimally disruptive products and procedures including: XLIF ® , MAS ® TLIF, MAS ® PLIF, ALIF, ILIF ® , Precept ™ , PCM ® Cervical Disc, Biologics, and our NVM5 ® neuromonitoring system.
- AANS Practical Courses (labs): NuVasive will participate in practical courses on Saturday, April 27 th and Sunday, April 28 th . The courses include extensive, hands-on offerings. Please visit http://budurl.com/AANSPracticalCourses for more details.
- Clinical Papers: Numerous invited podium presentations and entire sections of the AANS scientific program will be dedicated to lateral approach surgery with an emphasis on XLIF ® for both basic and advanced applications.
For more information on AANS 2013 please visit: http://Ez.com/AANS2013
For NuVasive Press Materials please visit: http://www.nuvasive.com/about-us/newsroom/
About AANS The American Association of Neurological Surgeons (AANS) is the organization that speaks for all of neurosurgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to promote the highest quality of patient care.
About NuVasive NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4 th largest player in the $8.2 billion global spine market. NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS ® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess ® , a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF ® , NuVasive has built an entire spine franchise. With over 80 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness ® .
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor Contact: Stephan Ogilvie VP, Corporate Development & Investor Relations NuVasive, Inc. 201-322-6515 Email Contact Media: Nicole Collins NuVasive, Inc. 858-909-1907 Email Contact
test123 kjk
